Key Dates

Related Announcements

• April 29, 2024 - Advancing HIV service delivery through pharmacies and pharmacists (R21 Clinical Trial Optional). See NOFO RFA-MH-25-186.

Issued by

National Institute on Drug Abuse (NIDA)

Purpose

This Notice informs potential applicants that the National Institute on Drug Abuse (NIDA) will participate in RFA-MH-25-186, “Advancing HIV service delivery through pharmacies and pharmacists (R21 Clinical Trial Optional”.   

Changes are made in Bold Italic 

Part 1. Overview Information

Components of Participating Organizations

National Institute of Mental Health (NIMH)

Office of AIDS Research (OAR)

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

National Institute of Allergy and Infectious Diseases (NIAID)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

National Institute on Minority Health and Health Disparities (NIMHD)

National Institute on Drug Abuse (NIDA)

Assistance Listing Number(s)

93.242, 93.847, 93.865, 93.855, 93.273, 93.310, 93.307, 93.279

Part 2. Full Text of Announcement

Section VII. Agency Contacts

Scientific/Research Contact(s):.

Angela Lee-Winn, PhD 
National Institute on Drug Abuse (NIDA)
Telephone: (301) 451-7206
Email: angela.lee-winn@nih.gov
 

Financial/Grants Management Contact(s)

Pamela G. Fleming
National Institute on Drug Abuse (NIDA)
Telephone: 301-480-1159
Email: pfleming@nida.nih.gov

All other aspects of the NOFO remain the same.

Inquiries

Please direct all inquiries to:

Angela Lee-Winn, PhD 
National Institute on Drug Abuse (NIDA)
Telephone: (301) 451-7206
Email: angela.lee-winn@nih.gov